Pharmalot… Pharmalittle… Good Morning
3 CommentsBy Ed Silverman // December 15th, 2008 // 7:04 am
Welcome back. We hope your weekend was enjoyable, or at least relaxing. Now, of course, the routine returns. And as always, there is much to do. So grab your morning coffee, or whatever, and dig in. Have a good day, everyone…
Par Pharmaceutical CFO Resigns (Yahoo/AP)
Schering-Plough Hepatitis C Drug Approved For Kids (Yahoo/AP)
Bayer To Increase R&D Spending (PharmaTimes)
Bristol, Sanofi Win Plavix Patent Battle (Bloomberg News)
Nathan
Isn’t it a little odd for Bayer to be announcing an increase in R&D spending less than a year after it closed two sites of R&D operations in the US? (link below)
http://www.forbes.com/markets/feeds/afx/2006/11/09/afx3160321.html
(although I’m a bit confused about whether Bayer AG is the same as the Bayer in the pharmatimes article linked by Ed)
Ed Silverman
Hi Nathan,
Yes, this is the same company. Here is the staetement Bayer issued on Friday…
http://www.bayer.com/en/News-Detail.aspx?id=11455
As to your question, which is a good one, I can only say ‘what a difference two years can make.’ However, the Bayer statement is short on specifics, unfortunately, so I don’t have a good answer. I’ve not seen a report from the press conference in Germany that offered further details either, although I will check.
Regards
ed
Peter
Nathan -
The announcement of increasing R & D expenditures made by BayerAG covers more than just their pharmaceuticals. The article also suggests increased R & D expenditures in the areas of MaterialScience and CropScience.
For example: “Between 2008 and 2012, Bayer CropScience intends to invest a total of EUR 3.4 billion in research and development.”
At the same time, Bayer also states they are looking for additional tax breaks and increased patent protections.